It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
XOM’s FA Score shows that 3 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
XOM’s TA Score shows that 5 TA indicator(s) are bullish while XRAY’s TA Score has 2 bullish TA indicator(s).
XOM (@Integrated Oil) experienced а -0.98% price change this week, while XRAY (@Medical Specialties) price change was -3.36% for the same time period.
The average weekly price growth across all stocks in the @Integrated Oil industry was +3.50%. For the same industry, the average monthly price growth was +4.50%, and the average quarterly price growth was -0.20%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.01%. For the same industry, the average monthly price growth was +3.93%, and the average quarterly price growth was -2.96%.
XOM is expected to report earnings on Jan 31, 2025.
XRAY is expected to report earnings on Feb 26, 2025.
Integrated oil companies are involved across nearly the entire oil value chain – from upstream operations like exploration and production, to downstream functions of refining and marketing. Exxon Mobil Corporation, Chevron Corporation and BP are major integrated oil companies. Their bottom lines’ response to crude oil prices could depend on the proportion of upstream vs. downstream businesses; for example, if a company has substantial downstream business, the adverse impact on their upstream business due to falling crude prices could be mitigated by benefits to its downstream business.
@Medical Specialties (-2.01% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
XOM | XRAY | XOM / XRAY | |
Capitalization | 461B | 6.69B | 6,889% |
EBITDA | 74.3B | 249M | 29,839% |
Gain YTD | 21.978 | -32.501 | -68% |
P/E Ratio | 13.16 | 19.23 | 68% |
Revenue | 335B | 3.97B | 8,449% |
Total Cash | 31.5B | 334M | 9,431% |
Total Debt | 41.6B | 2.3B | 1,809% |
XOM | XRAY | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 83 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 12 | 100 | |
SMR RATING 1..100 | 58 | 92 | |
PRICE GROWTH RATING 1..100 | 33 | 64 | |
P/E GROWTH RATING 1..100 | 26 | 89 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (6) in the Medical Specialties industry is significantly better than the same rating for XOM (89) in the Integrated Oil industry. This means that XRAY’s stock grew significantly faster than XOM’s over the last 12 months.
XOM's Profit vs Risk Rating (12) in the Integrated Oil industry is significantly better than the same rating for XRAY (100) in the Medical Specialties industry. This means that XOM’s stock grew significantly faster than XRAY’s over the last 12 months.
XOM's SMR Rating (58) in the Integrated Oil industry is somewhat better than the same rating for XRAY (92) in the Medical Specialties industry. This means that XOM’s stock grew somewhat faster than XRAY’s over the last 12 months.
XOM's Price Growth Rating (33) in the Integrated Oil industry is in the same range as XRAY (64) in the Medical Specialties industry. This means that XOM’s stock grew similarly to XRAY’s over the last 12 months.
XOM's P/E Growth Rating (26) in the Integrated Oil industry is somewhat better than the same rating for XRAY (89) in the Medical Specialties industry. This means that XOM’s stock grew somewhat faster than XRAY’s over the last 12 months.
XOM | XRAY | |
---|---|---|
RSI ODDS (%) | 2 days ago73% | N/A |
Stochastic ODDS (%) | 2 days ago62% | 2 days ago63% |
Momentum ODDS (%) | 2 days ago57% | 2 days ago68% |
MACD ODDS (%) | 2 days ago67% | 2 days ago59% |
TrendWeek ODDS (%) | 2 days ago57% | 2 days ago70% |
TrendMonth ODDS (%) | 2 days ago67% | 2 days ago71% |
Advances ODDS (%) | 16 days ago65% | N/A |
Declines ODDS (%) | 2 days ago55% | 7 days ago69% |
BollingerBands ODDS (%) | 2 days ago57% | 2 days ago45% |
Aroon ODDS (%) | 2 days ago52% | 2 days ago81% |